Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Daiichi Sankyo, ArQule’s tivantinib fails to meet primary end point in liver cancer study By PBR Staff Writer
Daiichi Sankyo and ArQule announced that the tivantinib has failed to meet its primary endpoint in a phase 3 liver cancer study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza meets primary endpoint in breast cancer study By PBR Staff Writer
A phase 3 study of AstraZeneca’s Lynparza (olaparib) met primary endpoint in a phase III trial in BRCA-mutated metastatic breast cancer.
Contract Research & Services > Clinical Trials > News Pfizer's Xeljanz goes head-to-head with AbbVie's Humira in RA study By PBR Staff Writer
Pfizer said its rheumatoid arthritis drug, Xeljanz, met primary endpoint in combination with methotrexate as compared to AbbVie's drug Humira, although it did not meet the primary endpoint on its own.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Ardelyx's tenapanor shows significant effect in hyperphosphatemia in phase 3 trial
By PBR Staff Writer
A phase 3 trial evaluating Ardelyx's tenapanor, a novel treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis, met its primary endpoint of significant difference in serum phosphorus levels.
Contract Research & Services > Clinical Trials > News
Woodley Equipment Company Exhibit at Outsourcing in Clinical Trials West Coast 2017
The Clinical Trials Team at Woodley Equipment Company is exhibiting at Outsourcing in Clinical Trials West Coast 2017, which is taking place at the Hyatt Regency San Francisco Airport on Wednesday 22nd and Thursday 23rd February
Contract Research & Services > Clinical Trials > Press Releases
ViiV Healthcare unveils positive study results for two-drug regimen for HIV
ViiV Healthcare has announced positive results from its phase 3 program assessing the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine.
Contract Research & Services > Clinical Trials > News
Merck halts clinical trial of Alzheimer's drug
By PBR Staff Writer
Merck said it will halt a phase 2/3 clinical study of an experimental Alzheimer’s drug due to lack of efficacy.
Contract Research & Services > Clinical Trials > News
Axovant's nelotanserin demonstrates treatment benefit in phase 2 dementia study
By PBR Staff Writer
Axovant Sciences said its drug nelotanserin has passed an early hurdle in a phase 2 study for Lewy body dementia, encouraging it to start preparing for a phase 3 study.
Contract Research & Services > Clinical Trials > News
Tracon's lead product candidate fails in phase 2 study in brain cancer trial
Tracon Pharmaceuticals said that data from a phase 2 study demonstrated that a combination of its endoglin antibody TRC105 with Avastin (bevacizumab) did not perform significantly better than Avastin alone for progression-free survival in patients with recurrent glioblastoma.
Contract Research & Services > Clinical Trials > News
Immunomedics, Seattle Genetics sign $2bn licensing deal for cancer drug
By PBR Staff Writer
Immunomedics has signed a development and licensing agreement worth up to $2bn with Seattle Genetics for its experimental cancer drug.
Contract Research & Services > Clinical Trials > News
Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients
Jazz Pharmaceuticals has enrolled its first patient for the Phase 2 clinical study of JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential option for excessive sleepiness (ES) in adult patients with Parkinson's disease.
Contract Research & Services > Clinical Trials > News
Viking's VK2809 demonstrates positive effect in POC study in glycogen storage disease
Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.
Contract Research & Services > Clinical Trials > News
Male contraceptive gel succeds in monkey trials
By PBR Staff Writer
A new type of male contraceptive polymer hydrogel which works by blocking sperm in the vas deferens has been successful in monkey trials.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests